FDA Medical Device Update

Slides:



Advertisements
Similar presentations
Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
Advertisements

What FDA Looks for When Inspecting IRBs and Sponsors Marian J. Serge Nurse Consultant Division of Bioresearch Monitoring Office of Compliance Center for.
Geoffrey Levitt Chief Counsel, Regulatory and Research Building a Culture of Compliance and Risk Management August 26, 2005.
Building Quality into Clinical Trials and Avoiding Common Pitfalls
Knowledge Dietary Managers Association 1 PART II - DMA Certification Exam Blueprint and Exam Development-
1 1 Medicare Marketing Danielle R. Moon, J.D., M.P.A. Director, Medicare Drug & Health Plan Contract Administration Group National Association of Health.
Effective Contract Management Planning
Investigational Device Exemption (IDE) Overview for IRBs
Regulatory Pathway for Platform Technologies
Investigational Device Exemptions 21 CFR Part 812
Device Initiatives FY 2005 Karen A. Coleman FDA Device National Expert.
Overview of FDA Device Regulations
Audits – VERIFYING EQUIVALENCE Presented by : Donald Smart Office of International Affairs Food Safety and Inspection Service.
Food Safety Quality Management System Training Guide
FDA Import Operations Overview Border Port Operations and Enforcement Vince Iacono, Compliance Officer U.S. Food and Drug Administration Southwest Import.
The Boston Seafood Show March 16, 2009 Presentation by: CDR Domenic J. Veneziano, Director, Division of Import Operations DIOP Division of Import Operations.
PREPARATION FOR FDA INSPECTION
Audit Ebru Mutlu-Omega CRO. General Purpose to help quality (to maintain quality at present) to assure quality (make sure that quality in future is maintained)
The IND and Clinical Trial Management Frances Richmond Director International Center for Clinical Trials.
Metric, Data and Analysis Biometrics Ricki A. Chase Director, Investigations Branch
What’s New in the FDA’s Pharmaceutical Inspectorate and Risk Based Systems Inspection Rick Perlman Chair Food, Drug, and Cosmetic Division ASQ.
What Does FDA Consider During a Food Facility Inspection? How will FSMA Change This? FDLI Enforcement, Compliance, and Litigation Conference December 9,
Proposed Rules under the FDA Food Safety Modernization Act
Vernon D. Toelle, Ph.D. Team Leader Pre-Market Compliance and Administrative Actions Team (BIMO Team) Overview of CVM Bioresearch Monitoring.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO.
MAGI's Clinical Trial Agreements, Budgets & Regulatory Conference FDA Inspections of Investigator Sites Paul Below Clinical Research Consultant P. Below.
FDA’s Pharmaceutical Inspectorate Robert Coleman National Expert Drug Investigator Food and Drug Administration.
CDRH Software Regulation
External Defibrillators: Recalls, Inspections, and the Quality System Regulation Melissa Torres Office of Compliance December 15, 2010.
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
FDA MedWatch and Patient Safety. Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006  The Act defines a ‘serious adverse event’
FDA Resources and Meetings FDA/EMA Orphan Designation and Grant Workshop Silver Spring, Maryland FDA Campus (White Oak) October 12, 2012 Bill Sutton Deputy.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
Ensuring Quality in Medical Device Clinical Trials
POSTMARKETING ADVERSE DRUG EXPERIENCE INSPECTIONAL PROGRAM CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO.
Ken Falci, Ph.D.,Director, OSAS Center for Food Safety and Applied Nutrition (CFSAN) FDA, College Park, MD.
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
FDA Regulatory review in Minutes: What Product Development Executives Need-to-Know. Specifically, frequent causes of recalls and related areas that investigators.
Carolyn Hommel Good Clinical Practice Program FDA February 25, 2004
Food and Drug Administration
Top 10 Medical Device Citations
Device Clinical Trials and More… Michael E. Marcarelli, PharmD Director, Division of Bioresearch Monitoring Office of Compliance Center for Devices and.
Best Practices: Where Industry Should Lead on Ensuring Proper Testing & Auditing Stephen F. Sundlof, DVM, PhD Senior Advisor for Animal and Food Safety.
Foreign Supplier Verification Programs Supplemental Proposal 1.
Overview of Gene Therapy Surveillance Inspections Joseph P Salewski, Chief Bioresearch Monitoring Branch CBER.
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
New England District Update MassMEDIC Conference December 1, 2010 Waltham, MA.
Competency-Development Project 08-October MDIC 2 What is the Competency-Development Project? ‏ Purpose: The purpose of this project is to improve.
UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.
1 BIORESEARCH MONITORING AND IN VITRO DIAGNOSTICS SYBIL WELLSTOOD, PH.D. OFFICE OF COMPLIANCE DIVISION OF BIORESEARCH MONITORING.
Enforcement Litigation and Compliance Washington, DC December 9-10, 2015 ORA and FDA District Directors Forum Randy Pack, Director, Compliance Branch,
FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,
Special Concerns Relating To Promotional Labeling And Advertising For Medical Devices.
U.S. Food and Drug Administration Food Protection Plan David W. K. Acheson, M.D., F.R.C.P. Associate Commissioner for Foods.
FDA Preventive Control Regulation Ernest Julian, Ph.D., Chief Office of Food Protection RI Department of Health AFDO 2014.
Complaint and recall 1. Title 21--food and drugs Chapter I- food and drug administration department of health and human services Subchapter A- General.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
NANCY CHOBIN, RN, AAS, ACSP, CSPM, CFER CHOBIN & ASSOCIATES CONSULTING HOT TOPICS IN STERILIZATION AND DISINFECTION.
FSMA TRAINING Industry Recall Readiness BEST PRACTICES.

American Society for Quality Region 5 Quality Conference
Overview of FDA Food Inspections
FDA Resources and Meetings
Linda M. Chatwin, Esq. RAC Business Manager, UL LLC
Tobey Clark, Director*, Burlington USA
New England District Update
Presentation transcript:

FDA Medical Device Update US Food and Drug Administration New England District

Position at NWE-DO Supervisory Investigator (May 2002) Monitor for Medical Device Program MDUFMA Coordinator

What is a Program Monitor?

Work for the District is in ~87 different program areas – examples: Foods Imported cheese Domestic Fisheries Infant formula Juice processing Pesticides …Many more Interstate Travel Dietary Supplements Blood banks Clinical Investigators Drug process inspections New Animal Drug inspections BSE (mad cow) Medical devices (Domestic and foreign) Mammography facilities

Program Monitoring All 87 programs are split among the 7 supervisors. Each has 12-14 programs for which s/he is the monitor

Investigations Branch Staffing Position 2006 2004 Consumer Safety Officers 64 85 Consumer Safety Inspectors 7 Supervisory CSOs 8

NWE-DO OEI 12/2006 12/2004 Total firms 8857 8365 Device firms 3004 2781 Class II and III firms 556 535

Program monitor role Identify the firms to be inspected or investigated Verify that assignments are created Assure the work is done and properly reported Try to keep OEI up-to-date Summarize accomplishments for management Be the Point of Contact for that program

Device Program – firm selection CDRH guidance Workplan Budget Staffing Inspectional History

CDRH Device Inspection Guidance Inspect 20% of Registered Domestic Class II and Class III Medical Device Manufacturers, i.e., 1,030. (NWE-DO: 98) Inspect 7% of Registered Foreign Class II and Class III Medical Device Manufacturers, i.e. 168 inspections. Conduct CDRH BIMO Inspections, i.e., 278 inspections.

CDRH Device Inspection Guidance For Cause MDUFMA – PMA/GMP inspections and other pre-market inspections including BIMO Follow-Up to Violative Inspections High/Significant Risk Class III and II Manufacturers Special Emphasis Focus on Firms with Repeated Violative Inspections Focus on Risk-Based Center Initiated Inspection Assignments

Risk-based Work Plan Initiative CDRH “Call for Proposals”. The Call process incorporates involvement from both Center and Field sources focusing on risks, hazards, justified concerns, and output from various databases to achieve those devices and eventual individual manufacturers, which indicate need for Agency inspectional resources. This is a directed inspection request with specific inspectional guidance in addition to GMP inspection.

FY’07 Device Workplan FY2007 FY2006 Level I 65 84 Level II 43 53 Compliance f/u 2 8 For Cause 7 9 High Risk Domestic --- Foreign 15 17 AP TOTAL 141 180

NWE-DO Staff Staff with devices as primary program = 12 Staff with devices as second program = 9

Training activities 10 CSOs to Basic Medical Device 2 CSOs to process validation 1 CSO to industrial sterilization 1 level II certification audit 2 level II certified 1 auditor certified 1 AP auditor certified

Pre-announcement of Inspection Most inspections are pre-announced NOT pre-announced: f/u to Compliance action (W/L, etc.) f/u to Complaint or informant f/u to observe promised corrections (VAI)

FY’06 District accomplishments QS/GMP Inspectional Accomplishments Domestic Foreign Total # OPS Planned 129 15 144 # OPS Accomplished 146 14 160

FY’06 Compliance actions 4 NWE-DO Medical Device firms had EI classified as OAI with Warning letter recommended 3 Warning letters issued

Summary of FY’06 Recalls Total recalls in NWE-DO = 212 Total CDRH recalls in NWE-DO = 145 Class 1: 15 Class 2: 116 Class 3: 14

Summary of Consumer Complaints (separate from MedWatch) FY’05 - 13 Consumer Complaints regarding Medical Devices 5 resulted in for-cause inspections FY’06 - 13 Consumer Complaints regarding Medical Devices 3 resulted in for-cause inspections

Summary of for- cause Inspections FY’05 +’06 f/u to verify corrections - 15 f/u to consumer complaint - 9 Inside informants – 7 Recall f/u – 8 CDRH Risk Based assignment - 6 f/u to violative EI @ another firm - 6 f/u to injury report – 2 Trade complaints – 2 Shipment of products not approved for US mkt – 1 Request of a State - 1

Summary of 483s 62/129 FY’06 device inspections had a 483 issued i.e. in 48% of Medical Device inspections vs. 47% of all product inspections in NWE-DO

Other FY’06 NWE-DO Medical Device accomplishments 3 Pre-Market Approval inspections 7 Post-Market Audit inspections 3 Non-clinical studies 6 IRBs (2 U/L) 5 Sponsor/Monitor/CRO (1 W/L) 7 Clinical Investigators 50 Mammography 52 Import Field Exams

Other FY’06 NWE-DO Medical Device accomplishments 2 AP inspections including one level 3 audit Candidate failed the audit, but then corrected and passed 2 NWE-DO firms approved for use of third party inspectors under the AP program

Contact Info William S. Boivin 781-596-7783 (phone) 781-596-7896 (fax) william.boivin@fda.gov